Table 2.
Baseline medications of study cohorts, prior to and after 1:1 propensity score-matching
| Prior to matching | Propensity score-matched | |||
|---|---|---|---|---|
| Abatacept | TNFi | Abatacept | TNFi | |
| N=13,015 | N=52,719 | N=11,248 | N=11,248 | |
| Prior use of biologic DMARDs | ||||
| Abatacept | 0% | 2% | 0% | 4% |
| TNFi | 64% | 0% | 58% | 0% |
| Adalimumab | 24% | 0% | 16% | 0% |
| Certolizumab | 4% | 0% | 2% | 0% |
| Etanercept | 24% | 0% | 16% | 0% |
| Golimumab | 4% | 0% | 3% | 0% |
| Infliximab | 21% | 0% | 20% | 0% |
| Prior use of non-biologic DMARDs | ||||
| Methotrexate | 56% | 69% | 55% | 55% |
| Hydroxychloroquine | 23% | 27% | 23% | 23% |
| Leflunomide | 18% | 14% | 18% | 18% |
| Sulfasalazine | 9% | 12% | 9% | 8% |
| Other* | 8% | 5% | 8% | 8% |
| Steroid use | ||||
| Steroid use | 70% | 69% | 68% | 67% |
| Recent steroid use (30 days prior) | 44% | 42% | 43% | 43% |
| Mean steroids cumulative dose 365 days in mg (SD) | 1235.9 (3484.3) | 1184.7 (9042.6) | 1192.9 (3572.8) | 1191.6 (6178.4) |
| Other Medications | ||||
| Antibiotics | 69% | 64% | 69% | 68% |
| Recent antibiotics (30 days prior) | 19% | 16% | 19% | 19% |
| Antiviral for zoster | 8% | 6% | 8% | 8% |
| Recent antiviral for zoster | 3% | 2% | 3% | 3% |
| NSAIDs | 44% | 54% | 43% | 42% |
| COXIBs | 11% | 11% | 11% | 11% |
| Opioids | 68% | 64% | 67% | 67% |
| Recent opioids (30 days prior) | 40% | 33% | 39% | 40% |
| Proton-pump inhibitors | 30% | 26% | 30% | 30% |
*
Other non-biologic DMARDs: cyclosporine, tacrolimus, azathioprine, auranofin, penicillamine